Format

Send to

Choose Destination
Cancer Res. 2018 Apr 15;78(8):2127-2139. doi: 10.1158/0008-5472.CAN-17-2649. Epub 2018 Jan 30.

Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.

Author information

1
H. Lee Moffitt Cancer Center, Integrated Mathematical Oncology, Tampa, Florida.
2
H. Lee Moffitt Cancer Center, Cancer Imaging and Metabolism, Tampa, Florida.
3
H. Lee Moffitt Cancer Center, Integrated Mathematical Oncology, Tampa, Florida. alexander.anderson@moffitt.org.

Abstract

Treatment of advanced cancers has benefited from new agents that supplement or bypass conventional therapies. However, even effective therapies fail as cancer cells deploy a wide range of resistance strategies. We propose that evolutionary dynamics ultimately determine survival and proliferation of resistant cells. Therefore, evolutionary strategies should be used with conventional therapies to delay or prevent resistance. Using an agent-based framework to model spatial competition among sensitive and resistant populations, we applied antiproliferative drug treatments to varying ratios of sensitive and resistant cells. We compared a continuous maximum-tolerated dose schedule with an adaptive schedule aimed at tumor control via competition between sensitive and resistant cells. Continuous treatment cured mostly sensitive tumors, but with any resistant cells, recurrence was inevitable. We identified two adaptive strategies that control heterogeneous tumors: dose modulation controls most tumors with less drug, while a more vacation-oriented schedule can control more invasive tumors. These findings offer potential modifications to treatment regimens that may improve outcomes and reduce resistance and recurrence.Significance: By using drug dose modulation or treatment vacations, adaptive therapy strategies control the emergence of tumor drug resistance by spatially suppressing less fit resistant populations in favor of treatment sensitive ones. Cancer Res; 78(8); 2127-39. ©2018 AACR.

PMID:
29382708
PMCID:
PMC5899666
DOI:
10.1158/0008-5472.CAN-17-2649
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center